Cyxone’s executive management team consists of experienced experts with solid knowledge in the fields of drug development, business development and financing in innovative biotech companies.
Born 1969. CEO since 2020.
Tara Heitner has more than 20 years’ experience from R&D, management and board positions in the biotech and pharma industry. Her previous roles include CEO, Business Development Director and Scientist. In 2014 Tara founded her own consultancy company, Heitner Biopharm Consultation, focusing on strategic, financing and business development advice for small biotech companies and start-ups. Tara is the co-founder of a number of start-ups spun out from universities such as Lund University, Sweden and Aarhus University, Denmark. Tara has successfully closed several partnership deals and been successful in fundraising. She holds a Ph.D. in chemistry from McGill University in Canada and an MBA from Technical University of Denmark (DTU).
Tara Heitner owns 33,660 shares in Cyxone.
Senior Executive Advisor
Born 1964. Senior Executive Advisor since 2021.
Ola Skanung holds a B.Sc. in Business Administration and Entrepreneurship and additional exams within Financial Law and Change Management. He has many years of experience as CFO and from working with start-ups and growth projects within the private sector, as well as with state and regional development actors.
Ola Skanung owns 28,700 shares in Cyxone.
Born 1970. COO since 2021.
Carl-Magnus Högerkorp holds a PhD in immunology from Lund University, as well as an MBA from EFL/Lund school of Economics and Management. He brings long and broad experience from pharma and biotech companies, both internationally and nationally. During his career, Dr Högerkorp has for example worked with research and development projects within infectious disease, immuno oncology, regenerative medicine, inflammation and autoimmune diseases. Further, he has held senior positions in several companies such as CEO for Edvince, Canimguide Therapeutics and ImModulate Pharma and CSO at Xintela, where he took part in the introduction of the company on Nasdaq First North Growth Market.
Born 1982. CFO since 2021.
Henrik Hang holds a B.Sc. in Business Administration. He has many years of experience as CFO and multiple finance positions in international companies and listed organizations in Sweden. Further, he has experience of listing company and fundraising.
Born 1951. CMO since 2021.
Cornel Pater is a board-certified physician in internal medicine and cardiology and holds a master’s degree in clinical epidemiology from the University of Rotterdam as well as a master’s degree in public health from the National School for Public Health in Utrecht. He has more than 20 years of experience in clinical pharmaceutical development from global key positions at companies such as Novartis, Hospira/Pfizer, Elan Pharma, Affibody, Takeda and Sandoz. He has also held roles as Global Medical Director Clinical Development at Novartis and as a consultant to several Swedish and Swiss pharmaceutical companies developing Covid-19-therapeutics. He has an extensive background as project leader within development of pharmaceuticals as well as medical technology products, ranging from designing preclinical and clinical trials and submission of regulatory trial applications to reporting clinical trial results and market launch of approved drugs.
Member of the Editorial Board of:
Rhea Rodeo has many years of work experience as HR assistant, Secretary, Administrator, and Project Administrator. Before joining Cyxone, she worked at large international companies in Sweden, such as Westinghouse and IKEA. At Cyxone, Rhea Rodeo is responsible for general administration and provides support and assistance to the CEO and CFO.
Phone: +46 708 88 21 72